Skip to main content
EVGN logo

Evogene Ltd.

EVGNNASDAQHealthcareBiotechnology

$0.40Today:- (-)1Y −68.76%

As of Oct 15, 2026 close

Market cap
$4.88M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.35$1.49
Volume (live)
-
Avg. volume (3M)
2.56M

Evogene (EVGN) Income Statement

Evogene reported revenue of $3.85M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 30.9% from $5.58M a year earlier. Evogene posted a net loss of $8.48M, compared with a net loss of $16.48M a year earlier. Gross margin was -6.3% and operating margin -364.2%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $347.00K, down 60.7% from the same quarter a year earlier.

Evogene Income Statement Analysis

Values in millions USD

Scroll to see more
Evogene Ltd. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue3.855.582.981.680.931.040.751.753.38
Cost of Revenue4.092.381.490.910.770.570.331.452.85
Gross Profit-0.243.201.490.770.160.470.420.300.54
Operating Expenses
Research & Development7.9912.5116.2020.7921.1317.2915.7914.6916.99
Selling, General & Administrative5.768.987.5310.429.997.995.795.605.50
Operating Expenses13.7921.9523.7027.7131.1225.2821.5920.2822.48
Operating Income-14.03-18.76-22.21-26.94-30.95-24.81-21.17-19.99-21.95
Other Income/Expense
Interest Income2.470.820.980.180.290.230.761.412.13
Interest Expense1.890.060.110.240.400.270.350.140.13
Other Income/Expense0.543.73-0.43-2.810.52-1.362.08-0.791.12
Income
Income Before Tax-13.50-14.81-21.95-29.75-30.43-26.17-19.09-20.78-20.83
Income Tax Expense0.000.010.020.090.010.030.020.030.01
Net Income-8.49-16.49-23.88-26.64-27.79-23.37-18.11-20.76-20.84
Net Income - Continuous Operations-8.49-14.82-21.97-26.64-27.79-23.37-18.11-20.76-20.84
Net Income - Discontinued Operations5.67-3.24-3.99------
EBITDA-12.20-13.36-20.53-27.01-27.88-23.21-16.02-18.76-18.68
EBIT-13.79-14.75-21.83-29.59-30.12-24.81---
Depreciation & Amortization1.141.381.302.582.232.732.772.022.15
Earnings Per Share
Basic EPS-1.00-3.00-5.00-6.00-1.00-1.00-1.00-1.00-1.00
Diluted EPS-1.00-3.00-5.00-6.00-1.00-1.00-1.00-1.00-1.00
Basic Shares Outstanding7.875.704.574.1241.0136.5525.7525.7525.73
Diluted Shares Outstanding7.875.704.574.1241.0136.5525.7525.7525.73

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Evogene Financial Statements

What was Evogene's revenue in fiscal 2025?

Evogene reported revenue of $3.85M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 30.9% from $5.58M a year earlier.

Is Evogene profitable?

No. Evogene reported a net loss of $8.48M in fiscal 2025. In fiscal 2024 it lost $16.48M.

What is Evogene's operating margin?

Evogene's operating income was −$14.03M on revenue of $3.85M in fiscal 2025, an operating margin of -364.2%, compared with -336.3% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition